Solventum Corp
Solventum develops, manufactures and commercializes healthcare products and services for hospitals, physicians, clinics and other healthcare providers around the world. Its products and services support patient care from prevention and diagnosis through treatment and recovery. Solventum is headquartered in Eagan, Minnesota. Solventum has three business segments. MedSurg offers wound care, skin care, surgical supplies, infection prevention products and medical technologies. Dental Solutions sells dental and orthodontic products, including brackets, aligners, restorative cements and bonding agents. Health Information Systems provides healthcare software for clinical documentation, coding, revenue cycle processes and data visualization. The company makes money by selling products and software through direct sales, distributors, key account management, inside sales and e-commerce, with local partners supporting sales in emerging geographies. It sells in over 90 countries.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SOLV in the last 7 days.
No SEC Form 4 filings for $SOLV in the last 30 days.
See all $SOLV insider activity →Solventum (SOLV) received FDA 510(k) clearance for combined use of Restrata and V.A.C. Therapy. This approval supports the company's wound care strategy, though adoption and revenue impact remain uncertain.
Solventum (NYSE: SOLV) will report Q3 fiscal 2026 earnings on November 5, 2026, after market close. Management will host a webcast to discuss results. Replay and financial disclosures will be available on the company's website.
Solventum (NYSE:SOLV) reported Q2 revenue of $2.21B, up 2.2% YoY, beating estimates. STERIS (NYSE:STE) reported $1.49B, up 7.3% YoY, in line with expectations. BD (NYSE:BDX) reported $4.98B, up 5.4% YoY, beating estimates. CONMED (NYSE:CNMD) reported $343.5M, flat YoY, beating estimates. Stocks reacted accordingly.
Recent SOLV coverage spans earnings, financial news and sector analysis.
Solventum (SOLV) received FDA 510(k) clearance for combined use of Restrata and V.A.C. Therapy. This approval supports the company's wound care strategy, though adoption and revenue impact remain uncertain.
This is a scheduled earnings setup that can drive pre-earnings positioning and implied volatility into Nov. 5.
Pure recap of already‑published earnings.
Deal process headline risk for SOLV, as valuation and buyer interest can swing expectations for proceeds and strategic focus.
Analyst target reduction signals potential downside for SOLV.
AlphAI scores every news story that mentions SOLV with an AI model for sentiment and relevance, and aggregates insider trades from Solventum Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Solventum (SOLV) received FDA 510(k) clearance for combined use of Restrata and V.A.C. Therapy. This approval supports the company's wound care strategy, though adoption and revenue impact remain uncertain.
1 min readSolventum (NYSE: SOLV) will report Q3 fiscal 2026 earnings on November 5, 2026, after market close. Management will host a webcast to discuss results. Replay and financial disclosures will be available on the company's website.
1 min readSolventum (NYSE:SOLV) reported Q2 revenue of $2.21B, up 2.2% YoY, beating estimates. STERIS (NYSE:STE) reported $1.49B, up 7.3% YoY, in line with expectations. BD (NYSE:BDX) reported $4.98B, up 5.4% YoY, beating estimates. CONMED (NYSE:CNMD) reported $343.5M, flat YoY, beating estimates. Stocks reacted accordingly.
2 min readSolventum (SOLV), a 3M (MMM) spinoff, is seeking offers for its Health Information Systems unit, valued at $5.5B to $7B. The business offers medical coding, billing, and documentation software to hospitals.
2 min readJefferies reduced its price target for Solventum Corp. (NYSE:SOLV) to $34 from $43, citing a sector selloff, while maintaining a Buy rating. The firm raised its EBITDA estimates by 7% to 13%, noting the company's $8.9 billion backlog and strong project execution. Solventum's Q2 earnings beat expectations with $2.55 EPS and $2.2B revenue, leading to an improved outlook. Stifel reiterated its Buy rating with a $100 target, adjusting growth estimates for the MedSurg division.
1 min readBTIG named Solventum Corporation (NYSE:SOLV) its top medical technology stock pick, maintaining a Buy rating and $95 price target. The firm cited growth potential, strategic initiatives, and strong Q2 results. Management expects a 4-5% organic growth rate and a 12-18 month separation of its Health Information Systems division. BTIG models 4% annual revenue growth and 9% EPS CAGR through 2028.
2 min readSeveral biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.
2 min readOn Friday, notable insider trading activity was reported for several US-listed companies. Global Water Resources (GWRS) directors bought shares, with Jonathan L. Levine acquiring 651,618 shares at $8.85 each. AEON Biopharma (AEON) director Timothy P. Lynch purchased 1.15M shares at $0.2117 each. Cloudflare (NET) president Michelle Zatlyn sold $28.3M worth of shares. Illumina (ILMN) director Keith A. Meister sold $145.56M in shares. InvestingPro analysis provided valuation insights for these comp
3 min readSolventum’s Q2 outlook is driven by its ERP transition wind-down, planned MedTech portfolio streamlining via a HIS separation, and execution of nearly 20 new product launches by early 2028. Management expects ERP cutover disruptions to subside after Q3. The HIS separation could dilute EPS depending on transaction structure. Solventum shares trade at $82.95.
3 min readMizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
5 min read
